Tag Archives: Sanofi

Sanofi files patent infringement suit against Merck Sharp & Dohme Corp. in US

PARIS, 10-Aug-2017 — /EuropaWire/ — Sanofi announced today that it filed a patent infringement suit against Merck Sharp & Dohme Corp. (“Merck”) on August 8, 2017 in the United States District Court for the District of New Jersey. In its suit Sanofi … Read the full press release

Sanofi’s Soliqua™ 100/33 now available by prescription in U.S. for the treatment of adults with type 2 diabetes

PARIS, 04-Jan-2017 — /EuropaWire/ — Sanofi announced today that Soliqua™ 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies. Soliqua 100/33 is indicated for the treatment of adults with type 2 … Read the full press release

Sanofi’s Merial and Boehringer Ingelheim’s CHC business swap successfully closed

Both companies will become global leaders in two different sectors of the pharmaceutical market Paris (France) and Ingelheim (Germany), 03-Jan-2017 — /EuropaWire/ — Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an … Read the full press release

Sanofi Pasteur and MSD to separately pursue their own vaccine strategies in Europe

PARIS, 03-Jan-2017 — /EuropaWire/ — Sanofi and its vaccines global business unit Sanofi Pasteur confirmed today the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). … Read the full press release

Sanofi welcomes Alan Main as EVP Consumer HealthCare

PARIS, 04-Oct-2016 — /EuropaWire/ — Sanofi today announced the appointment of Alan Main as Executive Vice President Consumer HealthCare, effective October 1st, 2016. Mr. Main will be a member of the Executive Committee and lead a newly created Consumer Healthcare … Read the full press release

Sanofi announces the appointment of Dr. Yong-Jun Liu as Head of Research, Global R&D

PARIS, 31-Mar-2016 — /EuropaWire/ — Sanofi announced today the appointment of Dr. Yong-Jun Liu as Head of Research, Global R&D, effective April 1, 2016. He will report to Dr. Elias Zerhouni, President, Global R&D. Dr. Liu is one of the world’s … Read the full press release

Dengue vaccine: Sanofi Pasteur’s Dengvaxia® receives regulatory approval in Brazil

Global introduction of the first Dengue Vaccine gains further momentum with this third approval in a row in an endemic country – With 1.4 million dengue cases reported this year, Brazil stands to gain tremendous value from this new dengue … Read the full press release

Sanofi: LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with or without metformin

LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone PARIS, 14-9-2015 — /EuropaWire/ —  Sanofi announced today that the LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with … Read the full press release

Sanofi’s subsidiary Genzyme to acquire Caprelsa® (vandetanib) from AstraZeneca

Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa®(vandetanib) from AstraZeneca Paris, France,  30-7-2015 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that it has entered into a definitive agreement with AstraZeneca to acquire Caprelsa® (vandetanib), a … Read the full press release

Sanofi, Regeneron Pharmaceuticals partner to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology

Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration Companies agree to jointly advance PD-1 and other new immuno-oncology antibodies – Sanofi commits to an initial investment of up to $2.17 billion in the exclusive collaboration, including $640 million in upfront payments to Regeneron … Read the full press release

Sanofi and its subsidiary Genzyme announced that US FDA granted Breakthrough Therapy designation to olipudase alfa

Investigational Enzyme Replacement Therapy to Treat Non-Neurological Manifestations which characterize Niemann-Pick Type B PARIS, 5-6-2015 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olipudase alfa. … Read the full press release

Robert Castaigne succeeds Dr. Klaus Pohle as Chairman of Sanofi’s Audit Committee

PARIS, 9-3-2015 — /EuropaWire/ — Sanofi today announced the appointment of Robert Castaigne as Chairman of its Audit Committee. Mr. Castaigne succeeds Dr. Klaus Pohle who has chaired Sanofi’s Audit Committee since 2004. This appointment is effective as of the Sanofi Board … Read the full press release

Sanofi and subsidiary Genzyme announced that FDA approved LemtradaTM (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS)

Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals PARIS, 17-11-2014 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has approved LemtradaTM (alemtuzumab) for … Read the full press release

Sanofi and MyoKardia, Inc. join forces to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies

Up to $200 Million Collaboration to Support Pioneering Science and New Treatments Paris and South San Francisco, CA, 18-9-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and MyoKardia, Inc., a privately-held company leading the development of precision therapies for genetic … Read the full press release

Sanofi and its subsidiary Genzyme announced positive interim results from the second year of the extension study of Lemtrada™ (alemtuzumab) for multiple sclerosis

In approximately 70 percent of patients, disability scores improved or remained stable for an additional two years beyond the two-year pivotal multiple sclerosis studies Approximately 70 percent of patients treated with Lemtrada did not receive a third course of treatment … Read the full press release

Sanofi: Genzyme’s Cerdelga™ capsules the only first-line oral therapy for certain adult Gaucher disease type 1 approved by FDA

Only First-Line Oral Treatment for Adult Gaucher Disease Type 1 Paris, 22-8-2014 — /EuropaWire/ — Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved Cerdelga™ (eliglustat) capsules, the only … Read the full press release

Sanofi and PATH announced the market debut for the first antimalarial treatments produced with semisynthetic artemisinin

First shipment marks a critical step in improving access to treatment worldwide Paris, France, and South San Francisco, United States, 19-8-2014 — /EuropaWire/ — Sanofi (Euronext: SAN and NYSE: SNY) and PATH today announced the delivery of the first large-scale batches of … Read the full press release

Sanofi and Medtronic partner to improve patient experience and outcomes for people with diabetes around the world

Initial focus on insulin-device combinations and care management services Paris and Minneapolis, Minn., 16-6-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Medtronic, Inc. (NYSE: MDT) today announced that they have signed a memorandum of understanding to enter into a … Read the full press release

Sanofi and Regeneron Pharmaceuticals presented positive results from Sarilumab Phase 3 Rheumatoid Arthritis Trial at European League Against Rheumatism Annual Congress in Paris

Both doses of investigational drug sarilumab met all three co-primary endpoints New data include major clinical response rates and ACR20 scores at 52 weeks Paris and Tarrytown, NY, 16-6-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, … Read the full press release

Sanofi’s investigational therapy Toujeo® consistently showed significantly fewer low blood sugar events compared with Lantus®

Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases in risk of low blood sugar events of up to 31% at night-time compared with Lantus® All studies in the phase 3 “EDITION” clinical trial program, including a … Read the full press release

Sanofi Pasteur announced its pediatric pentavalent vaccine Shan5™ received prequalification status from the World Health Organization

Shan5™ is the first vaccine jointly developed by the Indian company and its parent company Sanofi Pasteur  WHO’s decision allows for the purchase of Shan5™ by United Nations agencies Lyon, France, 7-5-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: … Read the full press release

Dr. Anne C. Beal appointed to the newly created position of Chief Patient Officer at Sanofi

Appointment is a First for a Top 10 Biopharmaceutical Company Paris, France,  1-4-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) today announced the appointment of Anne C. Beal, M.D., MPH, to the newly created position of Chief Patient Officer. « … Read the full press release

Alirocumab clinical studies to be presented by Sanofi and Regeneron Pharmaceuticals at American College of Cardiology’s 63rd Annual Scientific Session in Washington D.C. March 29-31

Companies To Host Investor Conference Call on Alirocumab on March 31 at 9 a.m. EDT Paris, France and Tarrytown, NY, 28-3-2014 — /EuropaWire/ — Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data … Read the full press release

Sanofi filed patent infringement suit against Eli Lilly over Lantus® and Lantus® SoloStar®

Paris, France, 31-1-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it filed a patent infringement suit against Eli Lilly and Company ( “Lilly”) on January 30, 2014 in the United States District Court for the District of Delaware. In … Read the full press release

RobecoSAM included Sanofi for seventh consecutive year in its 2014 Sustainability Yearbook 2014

Paris, France, 30-1-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that RobecoSAM, which measures the performance of companies in terms of corporate social responsibility (CSR), has included Sanofi for the seventh consecutive year in the 2014 Sustainability Yearbook published this month. … Read the full press release

Sanofi halts clinical trials and plans for regulatory filings with its investigational JAK2 inhibitor fedratinib

Paris, France, 21-11-2013 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the decision to halt all clinical trials and cancel plans for regulatory filings with its investigational JAK2 inhibitor, fedratinib (SAR302503). Following a thorough risk-benefit analysis, including consultation with the U.S. … Read the full press release

Sanofi announces it has successfully priced its €1 billion bonds due 2023 at 2.50%

Paris, France, 12-11-2013 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announces that it has successfully priced its offering of EUR 1 billion of notes, due 2023, bearing interest at an annual rate of 2.50%. The issue is drawn under the Company’s Euro … Read the full press release

U.S. FDA’s Nonprescription Drugs Advisory Committee recommends approval of Sanofi’s Nasacort AQ Nasal Spray for over-the-counter use in the U.S.

Treats Seasonal and Year-round Nasal Allergy Symptoms in Adults and Children  Paris, France, 06-8-2013 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration’s (FDA) Nonprescription Drugs Advisory Committee (NDAC) voted 10 to … Read the full press release

Sanofi vaccines division Sanofi Pasteur initiated Cdiffense Phase III Study of investigational vaccine for prevention of primary symptomatic Clostridium difficile infection (CDI)

Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide Lyon, France, 06-8-2013 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program … Read the full press release